Pharma Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating value for its members and his outlook for the next five years. Enrico, to start off, could you explain Assosalute’s…
Pharma The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international partnership strategy and how her diverse background in engineering, medicine and a variety of companies has equipped her to lead…
Pharma Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third largest pharma ophthalmic company in Europe, and the only pan-European ophthalmic company to have its headquarters on the continent, and…
Pharma Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the company’s products each year, talks about their extremely promising partnership with the Danish company Coloplast, and why partners from beyond…
Pharma Dr. Anna Maria Porrini, President of Boehringer Ingelheim Italy shares her vision for the company, how she intends to achieve it and where she sees opportunities for the company’s success in the market. Dr. Porrini, since we last spoke in 2009, Boehringer Ingelheim Italy has weathered the crisis and emerged…
Pharma The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive medicines, how the agency’s role is evolving in response and in which ways the agency can collaborate with the industry.…
Pharma Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented neo-epitopes combination, its plans to break into the immuno-oncology domain and its perspectives on the French regulatory and biotech environments, and emphasizes…
pharma Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic player across the whole of Europe and why 2015 was a significant year for the group, receiving European marketing approval…
Pharma The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws. He also discusses the issues of maintaining the sustainability of the French healthcare budget and the importance of increasing European…
Pharma Alessandra Modenese Kauffmann, General Manager of the Swiss Chamber of Commerce, shares her insights into the relationship between Italy and Switzerland, the Chamber’s efforts to foster trade between the two countries and the opportunities offered through close collaboration between Swiss and Italian companies. Alessandra, the chamber has been active in…
Pharma Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders, discuss how the company’s recent IPO will allow them to move forward…
Pharma Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel Chimos’ emphasis on innovation and R&D and discusses the promising orphan drug the company is in the process of developing. He…
See our Cookie Privacy Policy Here